MSLN and neoplasm: In vitro tumor cell killing assay revealed that ACOD1-/- MSLN-CAR-iMACs significantly increased anti-tumor activity (Fig. 6c), which could be dampened by supplementing a cell permeable 4-Octyl Itaconate (4-OI)19 (Fig. 6d).